HomeAI · summaries
Storia in 4 fonti
Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients - Pfizer (NYSE:
Pfizer's sigvotatug vedotin missed its Phase 3 OS goal in NSCLC but showed encouraging results in second-line patients.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
- ·
statnews.com
Closely watched Pfizer lung cancer drug falls short in clinical trial
Pfizer said an experimental drug it hoped could replace a widely used chemotherapy in one of the most common forms of lung cancer fell short in a clinical trial.
